ReviewFrontiers in immunology2026
PRDM1-mediated epigenetic and transcriptional repression mechanisms: a key hub in immune differentiation, tumor progression, and inflammatory responses.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PRDM1 is a key transcriptional repressor that plays a vital role in B- and T-cell differentiation, immune regulation, and tumor suppression. PRDM1 functions through its C2H2 zinc finger domains and proline-rich region, which mediate transcriptional repression by recruiting co-repressors like G9a and HDACs. Its expression is regulated by multiple signaling pathways, including JAK/STAT3 and CD40L, which control immune cell differentiation and function. PRDM1 is involved in cancer progression by regulating tumor suppression and metastasis, as seen in hepatocellular, colorectal, and breast cancers. Additionally, PRDM1 is implicated in autoimmune diseases such as lupus and rheumatoid arthritis, where it modulates B-cell differentiation and immune responses. Emerging evidence suggests that single nucleotide polymorphisms in the PRDM1 could serve as valuable biomarkers for disease diagnosis and prognosis. This review highlights the multifaceted roles of PRDM1 in disease pathogenesis and explores its potential as a therapeutic target for cancer and immune-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.